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Abstract
Background: Tumor metastasis is a frequent cause of treatment failure for cancer patients. A key
feature of metastatic cancer cells is their invasive ability. Cysteine proteases contribute to invasive
properties of many cancer cell types. To analyze the contribution of cysteine proteases to
metastasis we have over-expressed in B16 melanoma cells the natural cysteine protease inhibitor,
cystatin C. We measured in vitro invasion of cystatin over-expression clones with Boyden chamber
type assays. Tail-vein injections of cells were used to compare lung tumor colonization.
Subcutaneous tumor growth and tumor cell metastasis from primary tumors were also analyzed.
Apoptosis of tumor cells was measured in lung tissues following melanoma cell injection.
Results: Results show the in vitro invasion of cystatin C over-expressing cells was dramatically
inhibited. Lung tumor colonization was also reduced. Increased tumor cell apoptosis was found to
be an important factor and may be related to the reduced tumor burden noted in this system of
melanoma metastasis.
Conclusion: Cysteine proteases therefore, may be a target for future anti-metastatic therapies.
Background
Tumor metastasis is a major reason for treatment failure
in cancer patients. Invasion of host tissues is a hallmark
feature of metastasis and requires alterations in tumor cell
adhesion, cell migration, and proteolytic degradation of
tissue matrices [1,2]. A critical initial step of metastasis is
that tumor cells enter blood vessels or the lymphatic sys-
tem by invasion of host basement membranes. After being
dispersed through vascular spaces, metastatic tumor cells
lodge in distant capillaries. Late stages of metastasis
involve further steps including invasion from vascular
spaces into foreign tissues and growth of secondary metas-
tases in permissive environments (seed and soil hypothe-
sis) [2]. Growth of metastases in tissues also requires
invasion of host endothelial cells into tumor masses to
support further the metabolic needs of tumor growth [3].
Members of the papain cysteine protease family of
enzymes (primarily cathepsins B, H, and L) are elevated in
cancer cells and contribute to invasion of many tumor
types [4,5]. This high cysteine protease activity influences
the activity of other proteolytic enzymes during acquisi-
tion of an invasive phenotype [6]. Cysteine proteases help
create an invasive phenotype at one or more steps in
tumor progression to metastasis [7]. Details are lacking in
the exact roles of cysteine proteases in tumor progression,
but it is clear that highly metastatic variants of various
tumor types express an excess of protease activity of the
papain cysteine protease type [8]. Because elevated
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cysteine protease activity correlates well with highly inva-
sive cancers, inhibition of this activity may be a target for
anti-metastatic therapies.
Cystatins are potent inhibitors of cysteine proteases that
are found in all tissues and most biological fluids. In gen-
eral, a decrease in cysteine protease inhibitor levels is also
found in metastatic tumors, contributing to higher
cysteine protease levels [9]. Cystatin C is a type II cysteine
protease inhibitor that is normally secreted from cells
[10]. Previously we have investigated the role of the natu-
ral cysteine protease inhibitor, cystatin C, and found inhi-
bition of lung metastasis [11]. To help establish
mechanism of cystatin C action in metastasis we have
fused cystatin C to the N-terminus of green fluorescent
protein. In this study we show over-expression of cystatin
C in melanoma cells is associated with reduced metastasis
and increased apoptosis in lung tissues.
Results
Expression of cystatin C-GFP fusion
The expression of cystatin C-GFP fusion was observed in
B16F10 melanoma cells following transient transfection
of plasmid construct DNA. Confocal microscopy was used
in an attempt to localize cystatin C-GFP protein expres-
sion in cells. A cytoplasmic expression was noted for GFP
alone and cystatin C-GFP fusion when transiently
expressed in B16 melanoma cells (Figure 1). This pattern
of expression was not anticipated since cystatin C is pri-
marily a secreted protein that should have produced a
vesicular localization of fluorescence within the cell. Fig-
ure 2 shows expression of the cystatin C-GFP fusion pro-
tein. Cystatin C fused to GFP should be about 44 kD (30
kD GFP plus 14 kD cystatin) and has also formed multim-
ers under denaturing conditions. Recently Paraoan et al.
have described cytoplasmic distribution of human cysta-
tin C mutated within the signal peptide [16]. Similarly,
sequence analysis of RT-PCR product revealed a signal
peptide amino acid difference (-4 Ala→ Gly) between Balb
c (inserted cDNA) and B16 melanoma cystatin C messen-
ger RNA (endogenous) (data not shown). We recloned
the cystatin C-GFP fusion and re-transfected the DNA con-
struct and obtained identical results. We believe cystatin C
over-expression effects are primarily due to intracellular
expression in our B16 melanoma cell model.
Cysteine protease activity
The total cellular cysteine protease activity was measured
with a sensitive fluorometric assay. This assay indirectly
measures protease inhibitor levels in the cell as cystatins
are often found at low levels. Table 1 shows decreased
cysteine protease activity in cystatin C over-expression
clone c23. Most of the cellular cysteine protease activity is
localized to lysosomes that would be unaffected by
altered cystatin levels.
In vitro invasion of B16 melanoma is inhibited by cystatin 
C over-expression
One important characteristic of metastasis is the invasive
ability of tumor cells. We used an in vitro Boyden chamber
GFP fluorescence Figure 1
GFP fluorescence. B16 melanoma cells transfected with cystatin C-GFP fusion construct A, B) transiently transfected B16F10C) 
stably transfected B16F10 cells.Cancer Cell International 2005, 5:14 http://www.cancerci.com/content/5/1/14
Page 3 of 8
(page number not for citation purposes)
assay to quantify the invasive potential of our clonal lines.
[17]. Over-expression of cystatin C-GFP (c23, c28)
decreased the invasion of B16F10 melanoma cells
through Matrigel coated filters by about 90% relative to
control G1 cells (GFP transfected) (Fig 3). Cystatin-GFP
fusion clones behave similarly to cystatin over-expressing
clones without the GFP fusion. Growth rate is the same as
control; adhesion is the same as control; and cell migra-
tion is reduced in comparison to control ([12] and per-
sonal observations)
Cystatin C over-expression reduces lung colonization and 
increases survival in mice
We examined the effect of cystatin C over-expression on
lung tumor growth and overall survival of mice injected
via tail vein. Tail vein injections are measures of experi-
mental or late stage metastasis only because the initial
invasion and intravasation are bypassed. We hypothe-
sized that the large decrease measured for in vitro invasion
might lead to similar decreases in lung colonization in
mice. Although we measured a decrease in lung tumor
burden following tail vein injection in the cystatin C over-
expressing clone, this clone still resulted in tumor coloni-
zation (Table 2). We next examined the effect of cystatin
C over-expression on survival of mice injected with
B16F10 melanoma cells and found about a 10% increase
in median survival time (Figure 4). Our conclusion from
this data is that over-expression of cystatin C, while
decreasing tumor burden, causes only modest increase in
the survival of animals following tail vein injection of
melanoma cells. We show that a large decrease in
melanoma invasive ability with cystatin over-expression
does not by itself prevent subsequent growth of
metastases.
Western blot analysis of cystatin C-GFP fusion Figure 2
Western blot analysis of cystatin C-GFP fusion. Lane 1, human 
cystatin C, 1 ug; lane 2, c23 fusion clone (40 ug/lane total cell 
extract). Probed with anti-human cystatin C antibody. Fusion 
is 14 kD cystatin C plus 30 kD GFP protein ~44 kD. Multim-
ers form with denatured cystatin C.
Table 1: Cellular cysteine protease activity in vitro
Clone Activity* Relative activity %
G1 20 +/- 0.8 100
c23 15.6 +/- 0.7 78
*Arbitrary fluorescence units. Experiment carried out 3 times. 
Students t-test, p < .05.
Invasion assay Figure 3
Invasion assay. Boyden chamber type assays comparing cell 
line B16 F10, clone G1 (GFP-expressing), c23 and c28 (cysta-
tin C-GFP fusion) invasion through Matrigel. Experiment was 
run in triplicate with three filters for each clone per experi-
ment. Data is expressed in cells / filter ± s.d. Student's t test 
P < .001.Cancer Cell International 2005, 5:14 http://www.cancerci.com/content/5/1/14
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Subcutaneous growth of B16 melanoma with cystatin C 
over-expression is similar to control
We compared the subcutaneous growth of B16 melanoma
control and cystatin C over-expressing clones in syngeneic
C57 BL6 mice. Following subcutaneous, scapular injec-
tion of B16 melanoma tumor cells, tumors become
measurable by calipers after about ten days. Figure 5
shows the relative growth of subcutaneous tumors in
mice. A slight decrease in subcutaneous tumor growth was
noted for a cystatin C over-expression clone. In a separate
experiment we compared the relative lung metastasis of
melanoma cells originating from subcutaneous tumors.
These secondary lung metastases were quantitated at 14
days following subcutaneous injection of either clone G1
or clone c23. After sacrifice of the mice, tumor burden was
estimated by S100 staining of frozen lung tissue cross-sec-
tions. We found a significant reduction in lung metastasis
from primary subcutaneous tumors upon cystatin C over-
expression (Table 3).
Apoptosis of micrometastases is increased with cystatin C 
over-expression
We examined the distribution of both GFP labeled cells
and cystatin C-GFP labeled cells in lung tissue at 24 hours
following tail vein injection. The cystatin C-GFP fusion
product that we introduced into B16 F10 melanoma
allowed us to follow the distribution of metastatic cells in
animals. The melanoma cell density in the lung and
melanoma distributions were similar for both GFP
labeled and cystatin C-GFP clones (data not shown). This
observation suggests delivery of tumor cells for each clone
to lung capillaries is equivalent and cannot account for
differences in subsequent lung tumor burden. We instead
focused on tumor growth in late stage metastasis. An
examination of melanoma cell apoptosis at early times
after lung tissue seeding of melanoma cells provides
insight into tumor outgrowth at later stages. One week
Survival curve Figure 4
Survival curve. Comparison of survival of mice injected via tail-
vein with either clone G1 or c23 cells (7 mice per group).




G1 25 ± 12 12–45
C23 14 ± 5 5–23
* n = 6 mice for each clone
Subcutaneous tumor growth Figure 5
Subcutaneous tumor growth. Comparison of tumor volume of 
clone G1(control) or c23 (cystatin over-expressor). (4 mice 
per group) Paired Wilcoxon test P < 0.01.
Table 3: Melanoma metastasis to lung from subcutaneous 
primary tumors
Clone Average area ± s.e.m. (%_total)*
G1 26.0 ± 4.9
C23 4.3 ± 1.4
* Imaged S100 antibody positive staining for 4 tumors with 3 sections 
per tumor and three fields per section. (P = .005 for Student's t test).Cancer Cell International 2005, 5:14 http://www.cancerci.com/content/5/1/14
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after melanoma cell tail-vein injection, we excised lung
tissue and examined the levels of apoptotic cells. We used
the Dead-End TUNEL Assay to quantitate apoptotic cells
in frozen tissue sections. Figure 6 shows typical tissue sec-
tions stained for apoptotic cells at one week post-injec-
tion. Quantitation of apoptosis showed an average two-
fold increase in apoptotic melanoma cells within lung tis-
sue of animals injected with cystatin C over-expressing
cells (Table 4). Thus, increased apoptosis of lung metasta-
sized B16 melanoma cells correlates with decreased tumor
burden upon cystatin C over-expression.
Discussion
Blockade of the metastatic spread of cancer could provide
dramatic clinical improvements for the treatment of can-
cer patients. The therapeutic blockade of metastasis is a
formidable challenge due to many factors including
redundant invasion mechanisms of metastatic cells,
acquisition of chemotherapeutic resistance, and evasion
of host immune responses. In spite of these problems,
inhibition of metastatic cell invasion could be a possible
adjunctive treatment for metastatic disease. We have pre-
viously found cystatin C over-expression inhibits both
Apoptosis Figure 6
Apoptosis. Representative lung tissue sections stained for apoptosis with TUNEL reagents. A. Control (G1) cell injected mouse. 
B. c23 (cystatin C over-expressor) cell injected mouse.
Table 4: Apoptosis in lung tissue sections
Apoptotic cells/field
Mouse Clone G1 Clone c23 G1/C23 ratio
Expt 1 1 36 ± 3 78 ± 9 2.2
2 8.6 ± 1.5 44 ± 7 5.1
3 11.6 ± 1.3 25 ± 2.0 2.1
4 13.7 ± 2.0 26 ± 4.3 1.9
2.8 average
Mouse Clone G1 Clone c23 G1/C23 ratio
Expt 2 1 10.5 ± 1.6 35.8 ± 2.5 3.4
2 8.6 ± 0.8 20 ± 4.3 2.3
3 6.5 ± 0.8 12.2 ± 1.6 1.9
2.5 averageCancer Cell International 2005, 5:14 http://www.cancerci.com/content/5/1/14
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melanoma cell migration and metastasis [12]. In this
work, expression of cystatin C fused to GFP also showed a
dramatic inhibition of in vitro invasion of B16 melanoma
cells. The number of lung metastases following tail-vein
injection were decreased, however growth of subcutane-
ous melanoma tumors over-expressing cystatin C was
only slightly inhibited. The expression of cystatin C fused
to GFP we obtained exhibited primarily cytosolic localiza-
tion. Another group has reported cytosolic localization of
GFP-labeled cystatin C due to a signal peptide mutation
[16]. We have noted an amino acid change near the signal
peptide cleavage site and suggest abnormal cellular
distribution may result. The point is, our results on
melanoma metastasis may only pertain to intracellular
over-expression of cystatin C.
We have demonstrated cystatin over-expression in
melanoma cells appears to result in an increase in apopto-
sis in lung micrometastases in vivo. The growth of second-
ary metastases is considered to be rate limiting in the
metastatic cascade of tumor spread [18,19]. Over-expres-
sion of the metalloprotease inhibitor TIMP-1 does not
block B16 melanoma cell extravasation into lung tissue,
but does alter subsequent tumor growth within lung tis-
sue [20]. Our work supports the idea that inhibition of
cell invasion alone is not sufficient to prevent lung tissue
colonization by metastatic cells [21]. In this work we dem-
onstrate that apoptosis is increased in lung micrometas-
tases when melanoma cell invasion is inhibited by
cystatin C over-expression. Increased tumor cell apoptosis
may be the result of alterations in the tumor cell microen-
vironment in vivo, for example, alterations in tumor cell
adhesion or local release of growth factors required for
tumor cell survival. Inhibition of angiogenesis is probably
not involved because after at one-week analysis, virtually
all micrometastases were only a few cells in diameter.
Generally, angiogenesis begins only as tumor size
approaches 1 mm [22].
Additional effects cystatin on melanoma cell metastasis
might have been expected if our melanoma cystatin over-
expressing clones had secreted cystatin C. Multiple roles
extracellular cathepsin B have been suggested, including
matrix degradation [23]. A synthetic inhibitor of cysteine
proteases has been found to decrease metastasis in a colon
cancer model, however the point of metastatic block was
not defined [24]. Recently, Konduri et al. [25] have shown
over-expression of cystatin C in glioblastoma cells blocks
tumor cell invasion and tumor growth in vivo, however in
their system cystatin C was secreted.
Conclusion
Metastatic melanoma is a rapidly spreading and growing
cancer type that thwarts virtually all attempts at growth
arrest. Blockade of metastasis would improve current
treatments of melanoma that are primarily targeted at
tumor cell proliferation. We have found that cystatin C
over-expression dramatically reduces melanoma cell inva-
sion. Late stage metastasis is influenced for cystatin C
over-expressing cells by an apparent increased apoptosis
in the target tissue (in this case, lung). Our results indicate
that inhibition of cell invasion alone is insufficient to dra-
matically improve the survival of mice at late stage
melanoma metastasis. More favorable results may occur
at earlier steps of metastasis intervention with anti-inva-
sive agents or with combined therapies that target tumor
growth and /or angiogenesis.
Methods
Cell culture
The B16-F10 melanoma cell line was kindly provided by
Dr. I. Fidler (MD Anderson Cancer Center, Houston, TX).
Cells were grown in culture on plastic dishes as monolay-
ers in RPMI-1640 media containing 10% fetal bovine
serum (v/v) and supplemented with antibiotics (100 units
penicillin, 0.1 mg streptomycin, 0.25 µg amphotericin B
per milliliter) (Sigma). Cells were cultured in a 5% CO2
humidified atmosphere at 37°C until near confluence.
DNA constructs and cell transfections
Murine cystatin C cDNA was described in a previous paper
[12]. Fusion of cystatin C cDNA to the N-terminus of
green fluorescent protein (GFP) (Invitrogen) was carried
out with a fusion fragment comprised of two annealed oli-
gos (5'-CTGCAAAAATGCCA-3', 5'-
CGTGGCATTTTTGCAG3') (Integrated DNA Technolo-
gies, Corallville, Iowa). Ligated DNA was transformed
into DH5a E. coli cells by electroporation with a Biorad
Gene Pulser following the manufacturer's instructions.
Fusion clones were confirmed by restriction analysis and
lysis-purified DNA was used for transfection of B16
melanoma cells. Transfection of plasmid DNA into B16
F10 melanoma cells was carried out by the calcium phos-
phate method [13]. Transiently transfected cells were
imaged by confocal microscopy one or two days after
transfection. Stable transformants were selected in media
containing G418 (geneticin)(Sigma) at 1 mg/ml. Three
clonal lines were chosen for study after three weeks
selection: a GFP-control clone (designated G1) and two
cystatin over-expressing clones (designated c23 and c28).
Western blot analysis
B16 melanoma F10 clone c23 was grown to near conflu-
ence and lysed with buffer (0.1% Triton X-100 in PBS with
1% protease inhibitors (Sigma)) through three freeze
thaw cycles and centrifuged at 10 krpm for 5 minutes to
pellet cell debris. Cell extracts (40 ug) were run on 10%
SDS PAGE gels and electro-blotted to PVDF membranes
for antibody detection. Human cystatin C (1 ug) (Calbio-
chem) was run as a control. Rabbit anti-human cystatin CCancer Cell International 2005, 5:14 http://www.cancerci.com/content/5/1/14
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(Upstate Biotechnology) was used at 1:1000 dilution.
Secondary antibody, goat anti-rabbit HRP (Upstate Bio-
technology) was used at 1:1000 and detection was by ECL
luminescence system. (Amersham). Protein was deter-
mined by the Bradford assay.
Assay of cysteine protease activity
We used a fluorometric assay to measure total cellular
cysteine protease activity [14]. This assay indirectly meas-
ures cysteine protease inhibitor levels that are difficult to
measure directly due to low levels. Either G1 (GFP) or c23
(cystatin C-GFP fusion) cells were seeded at 5 × 104 cells
per well in a 24 well cell culture plate. After 16 hours
growth the cells were incubated with PAB buffer (Hank's
buffered saline plus 0.6 mM CaCl2, 0.6 mM MgCl2, 2 mM
cysteine, and 25 mM PIPES pH7.0) for 30 minutes at
37°C. The buffer was then replaced with 0.2 ml of the
same buffer containing 0.1% Triton X-100 and 100 uM Z-
Phe-Arg AMC (Enzyme Systems Products, Livermore, CA).
After 20 minutes further incubation at 37°C, fluorescence
was read in a BioTek flx800 fluorescent plate reader at 360
excitation/460 emission and the results were expressed in
relative fluorescence units. The assay was found to be lin-
ear for 30 minutes under the conditions used.
Cell invasion
Sub-confluent B16 F10 cells or permanently transfected
B16 melanoma clones were detached with trypsin/EDTA
solution (0.25%, 5 minutes) (Sigma). Following inactiva-
tion of trypsin by addition of an equal volume of serum-
containing media, the cells were counted with a hemocy-
tometer. Cells (2 × 104) were placed into top wells of
Boyden chambers (BD Biosciences), the filters (8 um pore
size, Osmonics, Inc.) pre-coated with Matrigel (65 ug/fil-
ter) [12]. Cell invasion was allowed to occur for 24 hours,
after which time cells were fixed and stained [methanol,
10 minutes; 0.1% Triton X-100, 2 minutes; Harris hema-
toxylin (Sigma), 10 minutes]. After 24 hours, cells on the
bottom of the filter were counted with an inverted Olym-
pus IMT-2 microscope at 400× magnification. Cell num-
bers for 18 fields were summed for each filter.
Survival curve
An experiment was conducted where mice (seven mice per
group) were tail vein injected (1 × 105 cells per mouse)
with either control GFP (G1) or cystatin C-GFP fusion
clone (c23). The mice were followed until time of death or
were moribund in which case mice were sacrificed.
Lung metastasis-assay
Clones G1 and c23 were grown to near confluence and
detached with trypsin solution. Trypsin was neutralized
with an equal volume of cell culture media and washed
twice with phosphate buffered saline (PBS). Cells were re-
suspended in PBS and 1 × 105 were injected into tail veins
of C57BL6 female mice (seven per group). After 30 days
mice were sacrificed and lung tissues were excised. Lung
surface tumors were counted under a low-power dissect-
ing microscope.
Subcutaneous tumor growth
Cells of clones to be tested (G1 and c23) were grown to
near confluence, detached with brief trypsin treatment,
and washed twice with PBS. After re-suspension in PBS,
the cells (3 × 105) were injected subcutaneously into
scapular regions of C57BL6 mice (six mice per group).
When tumors began to appear (after about ten days),
tumor diameter was measured on successive days in two
orthogonal directions with calipers. Tumor volumes were
calculated by the formula V = (a2 × b)/2, were a = width
and b = length, in millimeters [15].
Lung metastasis assay from subcutaneous tumors
C57BL6 mice (6 mice per group) were injected subcutane-
ously with either clone G1 or clone c23 cells at 2 × 105
cells per mouse. After 3 weeks mice were sacrificed and
lungs were removed and frozen in OCT media for section-
ing. Frozen tissue sections (10 uM) from each lung tissue
sample were stained with S100 antibody (DAKO, 1:1000
dilution) and immunologically detected with a secondary
horseradish peroxidase antibody (Sigma, 1:1000). Micro-
scopic images (100×) of stained tissue sections were col-
lected from 4 mice in each group. Quantitation of stained
area per section was carried out with Image J (NIH
software).
Apoptosis of lung tumor cells
Mice (C57BL6, 3–4 animals per group) were injected with
B16 F10 clones G1 (GFP), or c23 (cystatin C-GFP) at 1 ×
105 cells via tail vein. After one week mice were sacrificed
and lung tissue was removed. Lung tissues were stored in
OCT embedding compound (Miles Inc.) overnight at 4°C
and then frozen at -80°C. Frozen tissue sections (10 um)
were prepared and stained for TUNEL reactivity with the
Dead-End TUNEL kit (Promega) directly on glass cover-
slips. Manufacturers instructions were followed with side-
by-side staining of G1 and c23. Stained cells were
summed for at least five 200× microscopic fields per tissue
section and six independent sections per animal. The aver-
age number of apoptotic cells per high powered field were
recorded ± s.d.
List of abbreviations
GFP, Green fluorescent protein; AMC, 7-amino-4-methyl-
coumarin; PBS, Phosphate buffered saline; ECL, enhanced
chemical luminescence.
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